Table of Contents

About the Authors ............................................................... vii
Table of Chapters ................................................................... xiii
Preface .................................................................................. xlix
Acknowledgments .................................................................. li

Chapter 1  A Brief Introduction to the United States Patent System

David K. Barr

§ 1:1  Constitutional Basis of the Patent System and Sources of Governing Authority .......................... 1-2
§ 1:1.1  Constitutional Basis ...................................................... 1-2
§ 1:1.2  Sources of Governing Authority ................................. 1-2
§ 1:1.3  The America Invents Act ............................................ 1-4
§ 1:2  Patentable Subject Matter ............................................. 1-5
§ 1:3  The Patent Application ................................................. 1-5
§ 1:3.1  Examination of Patent Applications ......................... 1-7
[A]  General ........................................................................ 1-7
[B]  PTO Office Actions ..................................................... 1-8
[C]  Satisfaction of Requirements As of Filing Date .......... 1-9
[D]  One Invention per Patent ............................................ 1-10
[E]  One Patent per Invention ............................................ 1-10
§ 1:3.2  Claims to Priority ..................................................... 1-11
§ 1:3.3  Publication of Patent Applications ............................ 1-11
§ 1:4  Patent Term ............................................................ 1-12
§ 1:5  Post-Grant Actions .................................................... 1-13
§ 1:5.1  Reissue [35 U.S.C. § 251] ....................................... 1-13
§ 1:5.5  Supplemental Examinations [35 U.S.C. § 257]..... 1-18
§ 1:5.6  Certificates of Correction ........................................ 1-19
§ 1:5.7  Disclaimers .......................................................... 1-19
§ 1:6  Interferences and Interfering Patents; Transition from “First to Invent” to “First to File” ...... 1-19

Gerald Sobel & Daniel L. Reisner

§ 2:1 General ............................................................................. 2-2
§ 2:2 Research Teams .............................................................. 2-4
§ 2:2.2 Government-Funded Research: The Bayh-Dole Act .... 2-5
§ 2:2.3 Joint Inventions Made by Federal Employees and Private Parties ............................................. 2-6
§ 2:3 Research ........................................................................... 2-6
§ 2:3.1 Early-Stage Research ................................................... 2-6
§ 2:3.2 Drug Discovery ........................................................... 2-7
§ 2:4 Development .................................................................... 2-8
§ 2:4.1 Preclinical Development ............................................. 2-8
  [A] Form of the Active Compound ...................................... 2-9
  [A][1] Stereoisomers .............................................................. 2-11
  [A][2] Polymorphs .............................................................. 2-11
  [A][3] Salt Forms ............................................................... 2-11
  [A][4] Particle Size ............................................................ 2-11
  [A][5] In Vivo Conversion .................................................... 2-12
  [B] Formulation .................................................................. 2-12
  [C] Manufacturing Process ............................................... 2-12
  [D] Combination Therapies ............................................... 2-13
  [E] Methods of Treatment .................................................. 2-13
§ 2:4.2 Clinical Trials ............................................................. 2-13
  [A] The FDA Approval Process ......................................... 2-14
  [A][1] Clinical Studies and Trials ........................................ 2-14
  [A][2] Patent Term Restoration for FDA Delay .................... 2-16
  [B][1] ANDA Litigation ....................................................... 2-16
  [B][2] Data Exclusivity .......................................................... 2-17
§ 2:5 Patent Protection for Pharmaceutical and Biotech Inventions ............................................. 2-17
Chapter 3  Utility and Patentable Subject Matter Requirements

Daniel L. Reisner

§ 3:1  General

§ 3:2  Statutory Provision: Section 101

§ 3:3  Test for Utility: Brenner v. Manson

§ 3:4  Policy Behind Utility Requirement

§ 3:5  Threshold for Satisfying Utility Is Not High

§ 3:5.1  Satisfying Threshold in the PTO

§ 3:5.2  Satisfying Threshold in Litigation

§ 3:6  Utility for Pharmaceutical Inventions

§ 3:6.1  Pharmacological Activity Must Be Specified

§ 3:6.2  PTO’s Initial Burden

§ 3:6.3  Rebutting PTO with In Vitro and In Vivo Data and Relation to FDA Approval Process

§ 3:6.4  Examples

[A]  Sufficient Disclosure

[A][1]  Nelson v. Bowler

[A][2]  Cross v. Iizuka

[A][3]  In re Brana

[A][4]  Fujikawa v. Wattanasin

[B]  Insufficient Disclosure

[B][1]  Brenner v. Manson

[B][2]  In re Kirk

[B][3]  Kawai v. Metlesics

[B][4]  Rasmusson v. SmithKline Beecham

§ 3:7  Patentable Subject Matter

§ 3:7.1  “Processes”

§ 3:7.2  “Manufactures” and “Compositions of Matter”

§ 3:8  Patentable Subject Matter for Pharmaceutical Inventions

§ 3:8.1  “Processes”

[A]  Prometheus I

[B]  Prometheus II

[C]  Prometheus III and IV

[D]  Post-Prometheus

§ 3:8.2  “Manufactures” and “Compositions of Matter”

[A]  Diamond v. Chakrabarty

[B]  Association for Molecular Pathology v. Myriad Genetics

[B][1]  Myriad I, II, and III

[B][2]  Myriad IV

[C]  Post-Myriad
Chapter 4  Inventorship

Richard G. Greco & Daniel L. Reisner

§ 4:1 General Principles of Inventorship ........................................ 4-2
§ 4:1.1 Overview of Statutory Provisions .................................. 4-4
[A] Priority Disputes and the AIA ........................................ 4-4
[B] Priority Disputes [Pre-AIA] ......................................... 4-4
[C] AIA’s Elimination of Priority Disputes ........................... 4-5
§ 4:1.2 Conception ................................................................ 4-6
[A] Requirements .................................................................. 4-6
[B] Proof of Conception Requires Corroboration ................. 4-8
[C] Is There a Requirement That the Inventor Know That His Invention Will Work for Conception to Be Complete? .............................................. 4-9
[D] Unrecognized Accidental Creation Not Invention ............. 4-13
[E] Examples ....................................................................... 4-14
[E][1] General Goal with No Specific Means for Implementation: Amax Fly Ash Corp. v. United States .............................................. 4-14
[E][2] Providing Goal to Be Achieved without Direction: Morgan v. Hirsch ............................................ 4-14
§ 4:1.3 Reduction to Practice ................................................ 4-16
[A] Requirements .................................................................. 4-16
[B] Proof of Reduction to Practice Requires Corroboration ..... 4-17
§ 4:1.4 Simultaneous Conception and Reduction to Practice ........................................... 4-17
§ 4:1.5 Priority ..................................................................... 4-18
[A] Abandoned, Suppressed, or Concealed ......................... 4-19
[B] Diligence in Reducing Invention to Practice ................. 4-20
§ 4:2 Joint Inventorship: Distinguishing Inventive from Non-Inventive Contributions ......................... 4-21
§ 4:2.1 Statutory Provision: Sections 101, 116, and 256 .... 4-21
§ 4:2.2 Requirements for Joint Invention ............................ 4-22
[A] Determining Co-Inventorship ......................................... 4-22
[B] Assistance and Knowledge from One of Ordinary Skill Does Not Make One an Inventor ............. 4-22
§ 4:3 Incorrect Inventorship .................................................... 4-27
§ 4:3.1 Statutory Overview and Standard of Proof ................. 4-27
§ 4:3.2 Consequences of Naming the Wrong Inventors .... 4-27
§ 4:3.3 Correction of Inventorship ....................................... 4-28
[A] Statutory Basis: Section 256 ....................................... 4-28
[B] Deceptive Intent .......................................................... 4-28
Table of Contents

[C] Comment: An Odd Policy ........................................ 4-29
[D] Correction of Inventorship Versus Inequitable Conduct ........................................ 4-30
§ 4:3.4 Procedure for Correcting Inventorship .......... 4-30
[A] Correction During Litigation .............................. 4-30
[B] Correcting Inventorship in the Patent Office .... 4-31
§ 4:3.5 Adding Inventors Can Add Joint Owners ......... 4-31
[A] Examples ............................................................. 4-32
[A][1] Ethicon, Inc. v. U.S. Surgical Corp. ..................... 4-32
[A][2] Burroughs Wellcome Co. v. Barr Laboratories, Inc. .................. 4-32
[A][3] Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc. ........................................ 4-33
§ 4:4 Inventorship Issues for Particular Types of Inventions ........................................ 4-34
§ 4:4.1 Chemical Inventions ........................................ 4-34
§ 4:4.2 Nucleic Acid and Sequence Claims ................. 4-37
§ 4:5 Inventorship and Ownership ................................ 4-40
§ 4:5.1 Inventions by Employees .................................. 4-41
[A] Employment Agreements ................................... 4-41
[B] Shop Rights ......................................................... 4-43
[C] The Rights of Joint Inventors in the Absence of Agreement or Shop Rights .......... 4-44
[C][1] Joint Ownership ............................................... 4-44
§ 4:6 Anticipating and Resolving Joint Invention Issues ........................................ 4-47
§ 4:6.1 Putting Agreements in Place ............................ 4-47
§ 4:6.2 Including Warranties of Freedom to Assign .... 4-47
§ 4:6.3 Inventorship Checklists Before Research Begins ...... 4-48

Chapter 5 Patentability

Daniel L. Reisner, Aaron Stiefel, Richard G. Greco, Krista M. Rycroft & Sapna Walter Palla

§ 5:1 Introduction .......................................................... 5-9
§ 5:1.1 Presumption of Validity ....................................... 5-10
§ 5:1.2 Independent and Dependent Claims .................. 5-12
§ 5:1.3 Claim Construction Issues Relevant to Validity .... 5-13
§ 5:1.4 Grounds for Invalidity ......................................... 5-14
§ 5:2 Anticipation: An Invention Must Be Something New ........................................ 5-15
§ 5:2.1 Statutory Provisions: Sections 101 and 102 and the AIA ........................................ 5-15
[A] Section 102 (Pre-AIA) ............................................. 5-16
[B] Section 102 (AIA) .................................................... 5-17
[B][1] Overview .............................................................. 5-17
[B][2] Scope of Prior Art ................................................. 5-17
[B][3] Exceptions to Defined Scope of Prior Art ............ 5-18
[C] Differences Between Pre-AIA and AIA Versions of Section 102 ............................................ 5-19
[C][1] Change from First-to-Invent to First-to-File-or-Disclose ........................................ 5-19
[C][2] First-to-File-or-Disclose Examples .................... 5-19
[C][3] New Geographic Scope for Scope of Prior Art ...... 5-21
[C][4] Summary of Changes ........................................... 5-21
[D] Determining Which Version of Section 102 Applies .................................................................. 5-23

§ 5:2.2 Requirements for Anticipation ........................................ 5-23
[A] Art Must Include All Elements of a Claim to Anticipate ...................................................... 5-23
[B] Art May Anticipate Based Only on Limited Consideration of Information Beyond the Reference ........................................................................ 5-24
[C] Art Must Be Enabling to Anticipate ......................................................................................... 5-25
[C][1] Level of Disclosure .............................................................................................................. 5-25
[C][2] Enablement for Section 102(b) Art .................................................................................... 5-26
[D] Art May Anticipate by Inherency ............................................................................................. 5-27
[D][1] Examples of Inherent Anticipation...................................................................................... 5-28
[D][2] Examples of No Anticipation by Inherency .......................................................................... 5-30
[E] Art Disclosed Species Anticipates Genus Claim .................................................................... 5-31
[F] Art Disclosed Genus Generally Does Not Anticipate Species Claim ........................................ 5-32
[G] Art’s Use of Equivocal Language Generally Does Not Defeat Anticipation ............................. 5-33
[H] Art Need Not Be in Same Field As Invention to Anticipate .................................................. 5-34
[I] Device May Anticipate Claim to Method of Making .................................................................. 5-35

§ 5:2.3 Types of Prior Art ........................................................................................................ 5-35
[A] Printed Publications ................................................................................................................. 5-35
[A][1] Accessibility of Publication ................................................................................................ 5-36
[A][2] Publication Date .................................................................................................................. 5-36
[A][3] Examples ............................................................................................................................ 5-37
[A][3][a] Publication on FTP Site or Newsgroup ................................................................. 5-37
[A][3][b] Presentation at a Conference ......................................................................................... 5-37
[A][3][c] Nonconfidential but Limited Distribution ........................................................................ 5-38
[A][3][d] Thesis in University Library ......................................................................................... 5-39
[A][3][e] Publicly Available Patent Prosecution Documents ...................................................... 5-40
[B] Known or Used by Others in This Country ......................................................................... 5-40
[B][1] Known by Others .............................................................................................................. 5-41
Table of Contents

[B][2] Public Use ............................................................ 5-41
[B][2][a] Experimental Use Can Negate Prior
  Public Use ............................................................... 5-42
[B][2][b] Burden of Proof................................................. 5-43
[B][2][c] Evidentiary Factors ........................................... 5-43
[B][2][d] When Do Clinical Trials Fall Within the
  Experimental Use Doctrine and Negate
  Public Use? ............................................................ 5-44
[C] On-Sale Bar .............................................................. 5-46
[C][1] “Subject of a Commercial Sale” ............................. 5-47
[C][1][a] General Principles ............................................ 5-47
[C][1][a][i] Commercial Offer or Sale ............................. 5-47
[C][1][a][ii] Offer for the Patented Invention ................... 5-47
[C][1][b] Research Agreements ........................................ 5-48
[C][1][c] Granting Licenses ............................................. 5-48
[C][1][d] Method Claims ............................................... 5-49
[C][2] “Ready for Patenting” ........................................... 5-50
[D] First Patented in a Foreign Country ........................... 5-50
[E] Admitted Prior Art ................................................... 5-51

§ 5:3 Obviousness ................................................................... 5-51
§ 5:3.1 Statutory Provision: Section 103 ............................. 5-51
[A] The Obviousness Standard: Section 103(a) .................. 5-51
[B] Biotechnology Processes: Section 103(b) .................... 5-52
[C] The Co-Ownership/Joint Venture Exception
  to Prior Art .............................................................. 5-54
[C][1] Pre-AIA Section 103(c) ......................................... 5-54
[C][2] AIA Section 102(b)[2][C] ...................................... 5-56
[D] Incorporation of Section 102 Definition of
  Prior Art ...................................................................... 5-56
[D][1] Pre-AIA .................................................................. 5-56
[D][2] AIA ........................................................................ 5-57

§ 5:3.2 Overview of the Obviousness Question ..................... 5-57
[A] The Graham Factors ................................................... 5-57
[B] A Landmark Decision: KSR v. Teleflex ....................... 5-58
§ 5:3.3 Criterion for Obviousness ........................................ 5-60
[A] Combination of References/Prior Art Suggestion
  of the Invention ......................................................... 5-61
[A][1] Problem Solved by Invention ................................. 5-62
[A][2] Hindsight ............................................................. 5-63
[A][3] Number of References by Itself Does Not
  Determine Obviousness ............................................ 5-63
[A][4] Uncorroborated Expert Testimony Not
  Evidence of Obviousness ........................................... 5-64
[A][5] Art That Teaches Away from Invention ................... 5-64
[A][6] Prior Art Must Be Read As a Whole ....................... 5-66
[A][7] Inherency .............................................................. 5-66
[B] Predictability/Reasonable Expectation of Success .... 5-66
[B][1] The Standard........................................................ 5-66
[B][2] “Obvious to Try”.................................................. 5-70
[C] Enablement of Obvious Teaching Required .............. 5-71
[D] Unexpected Results .................................................. 5-71
[D][1] General Rule......................................................... 5-71
[D][2] Application to Pharmaceutical Patents................. 5-72
§ 5:3.4 Questions of Law and Fact....................................... 5-73
§ 5:3.5 Scope and Content of the Prior Art.......................... 5-75
[A] Analogous Art........................................................... 5-75
[B] Defining the Problem ............................................... 5-76
§ 5:3.6 “Ordinary Skill in the Art” Under Section 103....... 5-77
[A] Six Factors ................................................................ 5-77
[B] Skill in the Pharmaceutical Arts .............................. 5-78
[C] Relevance of the Inventor in Determining
   “Ordinary Skill in the Art” ......................................... 5-81
§ 5:3.7 Practical Evidence of Nonobviousness:
   The Secondary Considerations...................................... 5-82
[A] Long-Felt Need/Failure of Others......................... 5-84
[A][1] General Rule......................................................... 5-84
[A][2] Application to Pharmaceutical Patents................. 5-85
[B] Commercial Success ............................................. 5-88
[B][1] General Rule......................................................... 5-88
[B][2] Application to Pharmaceutical Patents................. 5-90
[C] Licensing ................................................................. 5-93
[C][1] General Rule......................................................... 5-93
[C][2] Application to Pharmaceutical Patents................. 5-93
[D] Copying ................................................................. 5-94
[D][1] General Rule......................................................... 5-94
[D][2] Application to Pharmaceutical Patents................. 5-94
[E] Near-Simultaneous Invention .................................. 5-95
[E][1] General Rule......................................................... 5-95
[E][2] Application to Pharmaceutical Patents................. 5-96
§ 5:3.8 Prior Art Disclosure of Genus Containing
    Claimed Species .......................................................... 5-96
§ 5:4 Written Description.................................................. 5-97
§ 5:4.1 Statutory Provision: Section 112........................... 5-97
[A] Written Description Is a Separate Requirement .... 5-97
[B] Controversy over Status of Written Description
   Requirement .............................................................. 5-97
[C] Written Description Requirement Applies to
   Priority Determinations and to Adequacy of
   Original Disclosure .................................................. 5-99
[C][1] Later Claims and Later Applications........................ 5-99
[C][2] Unsupported Original Claims............................... 5-100
§ 5:4.2 The Requirement

[A] The Purpose of the Requirement

[B] The Standard Set Forth by the Federal Circuit

[B][1] Basic Test

[B][2] Predictability and Other Factors

[B][3] Acceptable Forms of Description

[B][4] Fact Determination

[C] Conception and Written Description

§ 5:4.3 Genus and Species

[A] Claim Scope Must Correspond to Disclosure: Gentry Gallery

[A][1] Limiting Gentry

[A][2] Applying Gentry

[B] Species Based on a Disclosed Genus

[C] Genus Based on Disclosed Species or Examples

[D] Genus Based on Generic Description

[E] Range Cases

[F] Negative Limitations

[G] Unclaimed Optional Features

§ 5:4.4 Inherency

§ 5:4.5 Application to Particular Inventions

[A] Compound and Composition Claims

[B] DNA

[B][1] General Rule

[B][2] Deposits

[B][3] Genus Claims

[B][4] Possession of Polypeptides

[C] Antibodies

[D] Other Biological Material

§ 5:5 Enablement

§ 5:5.1 Statutory Provision: Section 112

§ 5:5.2 The Policy Behind Enablement

§ 5:5.3 Enablement: Question of Law

§ 5:5.4 Role of the Specification

[A] General Principles

[B] Means-Plus-Function Claims

§ 5:5.5 The Person Skilled in the Art

[A] Who Is the Person Skilled in the Art?

[B] What General Knowledge Does the Person Skilled in the Art Possess?

[C] Time Frame for Determining Enablement

[C][1] Enablement Measured As of Filing Date

[C][2] Using Post-Filing References to Show State of the Art at Filing

[C][3] Nascent Technology Must Be Disclosed

[C][4] Loss of Material Needed to Practice Invention
§ 5:5.6 Requirements for Enablement ....................... 5-131
[A] How to Make the Claimed Invention .................... 5-131
[A][1] Compound and Composition of Matter
Claims................................................................. 5-132
[A][2] Method of Use Claims................................. 5-133
[B] How to Use the Claimed Invention...................... 5-134
[B][1] Practical Utility........................................... 5-134
[B][2] Satisfying the How to Use Requirement............. 5-135
[B][3] Inoperability May Negate Enablement............... 5-137
§ 5:5.7 Enabling the Full Scope of the Claim.............. 5-138
§ 5:5.8 No Enablement If Undue Experimentation
Required .................................................................. 5-140
[A] Undue Experimentation: The Wands Factors........... 5-140
[A][1] Quantity of Experimentation Needed............... 5-141
[A][2] Direction or Guidance Provided/Working
Examples and Teaching Away................................. 5-143
[A][3] Nature of the Invention/State of Prior
Art/Level of Skill in the Art.................................... 5-144
[A][4] Predictability in the Art................................... 5-145
[A][5] Breadth of the Claim..................................... 5-146
[B] Routine Experimentation Is Allowed.................... 5-146
§ 5:5.9 Use of Deposits to Satisfy Enablement ............ 5-147
§ 5:6 Best Mode.......................................................... 5-149
§ 5:6.1 Overview.......................................................... 5-149
[A] Statutory Provision: Section 112........................ 5-149
[B] AIA’s Elimination of Best Mode As Grounds for
Invalidity or Unenforceability.............................. 5-149
§ 5:6.2 Purpose of the Best Mode Requirement............. 5-150
§ 5:6.3 Best Mode Distinguished from Enablement........ 5-151
§ 5:6.4 Best Mode: A Two-Prong Inquiry.................... 5-152
[A] Subjective Inquiry: Did the Inventor
Contemplate a Best Mode?.................................... 5-153
[A][1] Evidence of Inventor Preference....................... 5-153
[A][2] Alternative Embodiments Does Not
Mean There Is a Best Mode................................. 5-154
[A][3] Relevance of Inventor’s Intent to Conceal........ 5-154
[A][4] Intentional Concealment—Inequitable
Conduct.............................................................. 5-155
[A][5] Assignees........................................................ 5-155
[B] Objective Inquiry: Was the Best Mode Disclosed?...5-156
[B][1] Scope of Claimed Invention............................... 5-156
[B][2] Adequacy of Disclosure................................... 5-157
[B][2][a] Enablement.................................................. 5-157
[B][2][b] Disclosure That Mode Is Preferred................. 5-158
[B][3] Relevance of Prior Art....................................... 5-158
Starting Materials ................................................................. 5-159
Routine Features Need Not Be Disclosed ....................... 5-159
Mode of Commercial Production ........................................ 5-160
Disclosure of Special Materials or Identity of Supplier of Material ...................................................... 5-161
§ 5:6.5 Timing ........................................................................ 5-162
[Filing an Original Application] ........................................ 5-162
Continuation and Continuation-in-Part Applications ............................................................ 5-163
Foreign Priority Applications ........................................ 5-163
§ 5:6.6 Application to Pharmaceutical Patents ...................... 5-163
Public Deposit of Biological Materials ......................... 5-163
Claims to Pharmaceutical Compounds ......................... 5-165
Clinical Data ................................................................. 5-165
Synthesis of Intermediates Used to Make Claimed Compounds ........................................ 5-165
Purification of Claimed Compound ................................ 5-166
§ 5:7 Indefiniteness and the Requirement to Claim the Invention ................................................................. 5-166
§ 5:7.1 Statutory Provision: Section 112 ............................. 5-166
§ 5:7.2 The Requirements ..................................................... 5-167
Must Claim What Applicant Regards As the Invention ............................................................. 5-167
During Prosecution .......................................................... 5-167
Issued Patents ................................................................. 5-167
Indefiniteness .................................................................. 5-168
The Standard Set Forth by the Federal Circuit ................ 5-168
Role of the Jury ............................................................... 5-170
Dependent Claims .......................................................... 5-170
§ 5:7.3 Relationship of Indefiniteness to Other Determinations ................................................................. 5-171
Indefiniteness and Claim Construction .......................... 5-171
Indefiniteness and Infringement ...................................... 5-171
Indefiniteness Separate from Enablement ..................... 5-172
Indefiniteness and Prior Art .............................................. 5-173
§ 5:7.4 Indefiniteness in Different Situations ......................... 5-174
Terms of Degree ............................................................. 5-174
Patent Does Not Identify Test to Measure Claimed Property ......................................................... 5-175
Examples of Claims Found Indefinite ................................ 5-176
Other Examples ............................................................. 5-176

(Pharma/Biotech, Rel. #7, 11/14) XXV
Examples of Claims Found Definite .................. 5-177

Leading Example: PPG Industries, Inc. v. Guardian Industries Corp. .................. 5-177

Other Examples .............................................. 5-177

Single Claim to Both Method and Apparatus
Indefinite ............................................................ 5-178

Claims Requiring Knowledge or Intent ............... 5-180

Means-Plus-Function Claims ................................ 5-180

Drafting Errors in Claim Language .................... 5-182

Claims Found Indefinite ....................................... 5-182

Claims Not Found Indefinite ............................... 5-182

Lack of Antecedent Basis .................................... 5-183

§ 5:8 Double Patenting................................................. 5-183

§ 5:8.1 Two Forms of Double Patenting:
Statutory and Non-Statutory................................ 5-184

§ 5:8.2 The Policy Behind Double Patenting............... 5-185

§ 5:8.3 Double Patenting Requires Common
Inventorship or Ownership .................................. 5-186

§ 5:8.4 Situations in Which Double Patenting
May Arise .......................................................... 5-187

§ 5:8.5 Non-Statutory Double Patenting .................... 5-187

A. Anticipation and Obviousness........................ 5-187

B. Genus and Species ........................................... 5-189

C. The Test for Double Patenting ........................... 5-189

C][1] Two-Part Test ............................................. 5-189

C][2] Limited Use of the Specification .................... 5-190

C][3] Use of Prior Art ............................................. 5-191

C][4] Use of Post-Filing-Date Art ..................... 5-192

C][5] Claim-by-Claim Analysis ............................... 5-193

D. Who Is the Same Person for Purposes of
Double Patenting? ............................................... 5-193

E. Curing Double Patenting by Filing Terminal
Disclaimers ........................................................ 5-194

E][1] Effect of Filing a Terminal Disclaimer ........... 5-194

E][2] Need for Common Ownership of Patent
and Its Reference Patent ..................................... 5-195

E][3] The Timing of a Terminal Disclaimer Filing .... 5-196

E][4] Effect of an Extension of the Patent Term ....... 5-197

F. The Two-Way Double Patenting Test .................. 5-198

F][1] Requirements to Qualify for the
Two-Way Test .................................................. 5-198

F][2] Satisfying the Two-Way Test ......................... 5-199

G. Overlapping Claims ............................................ 5-199

§ 5:8.6 Safe Harbor Provision Involving Double
Patenting .......................................................... 5-200
[A] The Safe Harbor Requires a Prior Restriction by the Examiner .............................. 5-201
[B] The Safe Harbor Requires Consonance Between the Restriction Requirement and the Later Claims in the Later Application ..................... 5-201
[C] The Safe Harbor Requires Filing of a Subsequent Application Denominated a “Divisional” ............................................................ 5-202

§ 5:8.7 Double Patenting Issues in Pharmaceutical Patents ................................................ 5-204
[A] Method Patents over Prior Compound Patents .................................................. 5-204
[B] Examples ........................................................................................................ 5-205

§ 5:9 Inequitable Conduct ................................................................................................. 5-208
§ 5:9.1 Introduction ........................................................................................................ 5-208
§ 5:9.2 Inequitable Conduct Requires Proof of Materiality and Intent ............................... 5-210
§ 5:9.3 The Materiality Requirement .............................................................................. 5-211
[A] Standard for Materiality Before Therasense ...................................................... 5-211
§ 5:9.4 The Intent Requirement ..................................................................................... 5-214
[A] Actual Intent Required; Negligence Not Enough .............................................. 5-214
[B] There Must Be a Specific Intent to Deceive ....................................................... 5-214
[C] The Intent Requirement Under Therasense ....................................................... 5-215
[C][1] Proving Intent Before Therasense ................................................................. 5-215
[C][1][a] Ferring B.V. v. Barr Laboratories, Inc. ...................................................... 5-216
[C][2] Proving Intent After Therasense ................................................................. 5-217
[C][3] Whether the Actual Intent Standard Requires That at Least One Individual Have the Requisite Culpable State of Mind ....................... 5-218

§ 5:9.5 Categories of Inequitable Conduct ...................................................................... 5-218
[A] References ........................................................................................................... 5-218
[A][1] Non-Disclosed References ............................................................................ 5-218
[A][2] References Before the Examiner ................................................................. 5-219
[A][3] Disclosure Only of Abstracts ......................................................................... 5-219
[A][4] Potential Double-Patenting References ....................................................... 5-220
[A][5] Argument About a Reference ....................................................................... 5-220
[B] Descriptions of Data and Experiments ............................................................ 5-221
[C] Representations Regarding Inventorship .......................................................... 5-222
[D] Related Proceedings ......................................................................................... 5-223
[D][1] Related Patent Office Proceedings ............................................................ 5-223
[D][2] Related Litigations ......................................................................................... 5-224
[E] Miscellaneous Types of Inequitable Conduct ................................................. 5-224
[E][1] Application for Expedited Treatment ....................................................... 5-224
[E][2] Payment of Maintenance Fees ..................................................................... 5-225
[E][3] Disclosure of Relationships Between Declarant and Applicant .................................... 5-225
[E][4] Notes About a Presentation ........................................ 5-226
[E][5] Concealment of Best Mode .................................. 5-226
§ 5:9.6 Late and Corrected Disclosures .............................. 5-226
[A] Late Disclosures ................................................. 5-226
[B] Correcting a Disclosure During Prosecution .......... 5-226
[C] Disclosure in Reissue Proceedings ......................... 5-228
§ 5:9.7 Practical Problems in Pharmaceutical Patent Prosecution ........................................ 5-228
§ 5:9.8 Practical Advice for Defeating Inequitable Conduct Allegations ........................................ 5-230
[A] Disclosure of References ......................................... 5-231
[B] Disclosure of Experimental Details ....................... 5-231
[C] Disclosure of Experimental Data ............................. 5-232
[D] Care in Patent Prosecution ...................................... 5-232
§ 5:9.9 The Legal Effect of a Finding of Inequitable Conduct .................................................................. 5-233
[A] Inequitable Conduct Renders a Patent Unenforceable ................................................................. 5-233
[B] Inequitable Conduct May Result in Assessment of Attorneys’ Fees ........................................ 5-234
[C] Inequitable Conduct May Have Antitrust Consequences ................................................................. 5-234
§ 5:9.10 Procedural Aspects .................................................. 5-235
[A] Inequitable Conduct Is an Issue of Equity Decided by the Court, Not a Jury .......................... 5-235
[B] Standard of Review .................................................. 5-235

Chapter 6 Biological Deposits

Daniel L. Reisner

§ 6:1 Introduction .......................................................... 6-1
§ 6:2 The Evolution of Biological Deposits ......................... 6-2
§ 6:3 Biological Deposits Can Satisfy Disclosure Requirements .................................................. 6-3
§ 6:3.1 Written Description .................................................. 6-3
§ 6:3.2 Enablement .......................................................... 6-4
§ 6:3.3 Best Mode ............................................................ 6-4
§ 6:4 Biological Deposits Not Required If Disclosure Otherwise Adequate ........................................ 6-5
§ 6:5 Making and Maintaining Biological Deposits .......... 6-5
Chapter 7  Types of Biological and Pharmaceutical Patents

David K. Barr, Sylvia M. Becker, Patricia Carson, Richard G. Greco, Daniel L. Reisner & Aaron Stiefel

§ 7:1  Research Tools ............................................................... 7-7
§ 7:1.1  What Is a Research Tool Patent? ................................ 7-8
§ 7:1.2  Utility Requirement for Patenting Research Tools ......................... 7-10
§ 7:1.3  Research Tools Used to Obtain Data for FDA Submissions: Section 271(e)(1) .................................. 7-11
§ 7:1.4  Off Shore Development Work: Section 271(f) and (g) ...................... 7-13
[A]  Section 271(f) .................................................................. 7-14
[A][1]  The Statute .................................................................. 7-14
[A][2]  Legislative History .......................................................... 7-14
[A][3]  Applying Section 271(f) to Research Tools ................................ 7-15
[B]  Section 271(g) .................................................................. 7-15
[B][1]  The Statute .................................................................. 7-15
[B][2]  Legislative History .......................................................... 7-16
[B][3]  Applying Section 271(g) to Research Tools ................................ 7-16
§ 7:2  Patentability of Chemical Compounds ........................................ 7-17
§ 7:2.1  Novelty of a Claim to a Chemical Compound Over the Prior Art: The Requirement That an Anticipating Reference Be Enabling ........................................ 7-18
§ 7:2.2  Obviousness of a Claim to a Chemical Entity and the Impact of the Supreme Court’s Decision in KSR ................................................................. 7-19
[A]  Prima Facie Obviousness ...................................................... 7-23
[A][1]  An Evidentiary Mechanism ............................................... 7-23
[A][2]  Demonstrating Prima Facie Obviousness ............................. 7-24
[A][2][a]  Properties of Claimed and Prior Art Compounds ............... 7-25
[A][2][a][i]  New Property Alone Does Not Defeat a Prima Facie Case .................................................. 7-25
[A][2][a][ii]  To Demonstrate Prima Facie Obviousness, a Prior Art Compound Must Suggest Some Useful Property .................................................. 7-25
[A][2][a][iii]  In re Dillon ............................................................... 7-26
[A][2][b]  Prima Facie Obviousness Based on Similarity in Structure: “Structural Obviousness” .................................................. 7-27
[A][2][b][i]  Pre-KSR Federal Circuit Decisions .............................. 7-27
[A][2][b][ii]  Post-KSR Federal Circuit Decisions ............................ 7-33
[A][2][b][iii]  Post-KSR District Court Decisions .............................. 7-43
[A][2][c]  Reason to Combine ...................................................... 7-46
Nonobviousness Where Prior Art Teaches Away from Claimed Compound ........................................ 7-48

Examples from Pre-KSR Decisions ........................................ 7-49

Finding Structural Obviousness ........................................... 7-49

Finding No Structural Obviousness ....................................... 7-51

Rebutting a Prima Facie Case of Obviousness ...................... 7-54

Unexpected Results Require a Showing of Actual Differences ......................................................... 7-55

Compared to Closest Prior Art .............................................. 7-55

Differences Must Match Scope of Claim .............................. 7-56

Magnitude of Difference in Properties .................. 7-56

Multiple Properties .......................................................... 7-57

Evidence of Unexpected Properties Not Limited to Specification ......................................................... 7-59

Evidence Need Not Be in Specification ................................ 7-59

Unexpected Property Need Not Be in Specification ............. 7-60

Illustrative Cases .............................................................. 7-61

Prima Facie Obviousness Rebutted ...................................... 7-61

Prima Facie Obviousness Not Rebutted ............................. 7-62

Genus and Species Inventions ............................................ 7-65

Anticipation of a Chemical Genus by a Prior Art Species .......... 7-66

Prior Species Anticipates Genus ........................................ 7-66

Conception of Species Before Prior Art Can Defeat Anticipation of Broader Genus ..................... 7-67

Validity of a Claimed Species Over a Prior Art Genus .............. 7-68

Anticipation of Chemical Species by a Prior Art Genus .............. 7-68

General Rule .................................................................... 7-68

Exception for Small Prior Art Genus: In re Petering .............. 7-69

Obviousness of a Chemical Species Over a Prior Art Genus .......... 7-70

General Rule ................................................................. 7-70

Prima Facie Case Based on Prior Art Genus Can Be Rebutted .... 7-71

Size of Prior Art Genus and Nature of Examples May Negate Prima Facie Case .......... 7-71

In re Jones .................................................................... 7-72

In re Baird .................................................................... 7-72

Written Description Support for Genus and Species Composition Claims ............................................... 7-73

Species or Subgenus Claims ................................................ 7-73

Genus Claims ................................................................. 7-74
Table of Contents

§ 7:2.4 Stereoisomers, Enantiomers, and Diastereomers ........................................................... 7-75
[A] Introduction ........................................................................................................ 7-75
[B] Patentability of Stereoisomers ........................................................................... 7-78
[B][1] Anticipation ..................................................................................................... 7-78
[B][2] Obviousness .................................................................................................... 7-80
[C] Claim Construction and Infringement ............................................................... 7-85

§ 7:2.5 Polymorphs ........................................................................................................... 7-86
[B] Techniques for Identifying Polymorphs ............................................................... 7-87
[B][1] X-Ray Powder Diffraction ................................................................................ 7-88
[B][2] Single Crystal X-Ray Crystallographic Analysis ........................................... 7-88
[B][3] Infrared Absorption Analysis ........................................................................... 7-88
[C] Infringement ......................................................................................................... 7-89
[C][1] Evidentiary Issues ............................................................................................ 7-89
[C][2] Quantity Required ........................................................................................... 7-91
[C][3] Conversion ....................................................................................................... 7-93
[C][4] Claim Construction .......................................................................................... 7-95
[D] Validity ................................................................................................................ 7-95
[D][1] Inherent Anticipation ....................................................................................... 7-95
[D][2] On-Sale Bar ...................................................................................................... 7-96

§ 7:2.6 Pharmaceutical Salts of Active Ingredients ...................................................... 7-97
[B] Development of Pharmaceutical Salts .................................................................. 7-97
[C] Patentability of New Salts ....................................................................................... 7-98
[C][1] Determinations of Obviousness/Nonobviousness of New Salt Forms of Compounds ........................................................................................................... 7-98
[C][2] Most Common Salt Form Used for Known Active Found Obvious in Obviousness-Type Double Patenting Analysis .............................................................................. 7-103

§ 7:2.7 Infringement by Conversion to a Patented Form ..... 7-104
[A] In Vivo Conversion ................................................................................................ 7-105
[A][1] Claim Construction .......................................................................................... 7-105
[B] Infringement and Anticipation ............................................................................. 7-107
[B][1] Schering v. Geneva .......................................................................................... 7-107
[B][2] Pre-Schering District Court Decisions ............................................................... 7-108
[B][2][a] Marion Merrell Dow .................................................................................... 7-109
[B][2][b] Omeprazole ................................................................................................ 7-110
[B][2][c] Buspirone .................................................................................................... 7-112
[C] Conversion Outside the Body: Polymorphic Form Conversion ................................ 7-113

§ 7:2.8 Particle Size of Active Ingredient ................................................................. 7-114
[A] What Is Particle Size? .......................................................................................... 7-114
[B] Infringement of Particle Size Patents .................................................................. 7-115
[B][1] Measured on the API Raw Material or in the Formulation ................................ 7-115
Infringement of Particle Size Patents in Hatch-Waxman Cases ........................................ 7-117
Method of Measurement........................................ 7-118
Infringement Under the Doctrine of Equivalents ................................................................... 7-119
Validity ................................................................. 7-119
Obviousness ........................................................... 7-119
Written Description................................................. 7-120
Pharmaceutical Formulations....................................... 7-121
What Is a Pharmaceutical Formulation? ................ 7-121
Claim Construction Issues......................................... 7-127
"Solubilizer" Limited to Surfactants....................... 7-127
"Lipophilic Component" Construed to Include More Than Surfactants ......................... 7-128
Claim Not Limited to Particular Grade of an Excipient......................................................... 7-128
Purity Limitations .................................................. 7-129
"Hydrosol" Limited to "Medicinal Preparation" .... 7-129
"Saccharides" Includes "Polysaccharides" ..................... 7-130
Literal Infringement and Infringement Under the Doctrine of Equivalents .................... 7-131
Using Different Excipients ..................................... 7-132
Non-Equivalence .................................................... 7-132
Prosecution History Estoppel ............................. 7-133
Controlled Release Formulations: Foreseeability of Substitution .................................. 7-133
Prosecution History Estoppel Bars Equivalence....7-133
No Prosecution History Estoppel ....................... 7-134
Controlled Release Formulations: Prosecution History Estoppel ......................................... 7-135
Infringement by Equivalents: No Dedication of Equivalent Excipient ................................ 7-136
Patent Validity ........................................................ 7-137
Obviousness ........................................................... 7-137
Combinations of Excipients ............................... 7-137
Combination Therapies ........................................... 7-139
Obvious Combination ............................................ 7-139
Nonobvious Combination ....................................... 7-140
Pharmacokinetic/Pharmacodynamic Limitations ................................................................. 7-141
Written Description................................................. 7-142
Enablement............................................................. 7-142
Bibliography of Pharmaceutical Formulation Treatises and Texts .................................... 7-143
Method of Treatment ................................................ 7-144
Table of Contents

§ 7:4.2 Patentability of Method of Treatment Claims .......................... 7-145
§ 7:4.3 Conception ............................................................. 7-146
§ 7:4.4 Claim Construction Issues ..................................... 7-146
[A] Preambles ..................................................................... 7-146
[A][1] Preambles Can Be Limiting .................................... 7-147
[A][2] Construing Preambles in Method of Treatment Claims ........... 7-147
[A][3] Adding Method of Treatment Preamble Language by Amendment Can Render Preamble Limiting ........................................ 7-148
[B] Specific Claim Terms ............................................. 7-149
[B][1] “Treat” ................................................................ 7-149
[B][2] “Effective Amount” ............................................ 7-149
[B][3] “Co-Administration” ............................................. 7-150
§ 7:4.5 Prior Art Invalidity ................................................. 7-151
[A] Inherent Anticipation ............................................. 7-151
[A][1] Examples of Inherent Anticipation .................... 7-151
[A][2] Examples of No Anticipation by Inherency ................. 7-154
[B] Prior Art Need Not Disclose Efficacy to Anticipate ................. 7-156
[C] Obviousness ............................................................ 7-157
§ 7:4.6 Written Description ................................................ 7-158
[A] Examples of Method of Treatment Cases Involving Written Description ................................................................. 7-158
[B] Field of Use Claim ................................................. 7-158
[C] Dosing ..................................................................... 7-159
§ 7:4.7 Enablement............................................................. 7-160
[A] Compound Needed to Practice Claim Must Be Enabled ............... 7-160
[B] Dosing ..................................................................... 7-160
§ 7:4.8 Best Mode............................................................... 7-161
§ 7:4.9 Infringement........................................................... 7-161
[A] Suing the Maker of the Therapeutic: Indirect Infringement ........ 7-161
[B] Suing on Method of Treatment Claims Against an ANDA Defendant ................................................................. 7-162
§ 7:5 Pharmaceutical Manufacturing ....................................... 7-162
§ 7:5.1 Intermediates.......................................................... 7-163
[A] Definition and Purpose ........................................ 7-163
[B] Utility Required ...................................................... 7-163
§ 7:5.2 Product-By-Process Claims ...................................... 7-166
[A] Definition and Purpose ........................................ 7-166
[B] Construction of Product-By-Process Claims ......... 7-167
[B][1] Patent Office Examination of Pending Product-By-Process Claims ................................................................. 7-167
Construction of Issued Product-By-Process Claims in Patent Infringement Litigation ........ 7-168

§ 7:5.3 Process Claims ....................................................... 7-171
[A] Definition and Purpose ............................................. 7-171
[B] Patentability of Process Claims .............................. 7-171
[C] Biotechnological Processes .................................... 7-172

§ 7:6 Nucleic Acid Patents .................................................... 7-173

§ 7:6.1 The Promise of Genomics ...................................... 7-173
[A] First Recombinant DNA Organism ........................ 7-173
[B] Cellular Factors for Making Proteins ...................... 7-173
[C] Genetic Basis of Disease .......................................... 7-174
[D] Gene Therapy ............................................................ 7-174
[E] Our Expanding Knowledge of Genes ......................... 7-175
[F] Biotechnology Patents ............................................. 7-176

§ 7:6.2 Eligibility of Nucleic Acid Sequences for Patenting ........................................... 7-177
[A] Product of Nature Exception to Patentability .......... 7-177
[A][1] Patentability of Man-Made Living Organisms: 
Diamond v. Chakrabarty ........................................... 7-178
[A][2] Purified and Isolated ............................................. 7-179
[A][2][a] Kuehmsted v. Farbenfabriken of Eberfield .... 7-180
[A][2][b] Merck & Co. v. Olin Mathieson ..................... 7-180
[B] Cases Suggesting Natural DNA Sequences Not Patentable ........................................... 7-181
[B][1] Funk Bros. v. Kalo ............................................. 7-182

§ 7:6.3 Utility Requirement for Nucleic Acid Patents ........ 7-184
[A] PTO Board of Patent Appeals Decisions ................. 7-185
[B] The PTO’s Utility Examination Guidelines 
and Training Materials ............................................. 7-187
[B][2] The 1999 Revised Utility Guidelines ................. 7-188
[B][3] The 2001 Utility Guidelines .................................. 7-188
[B][4][a] “Specific” Utility ............................................ 7-190
[B][4][b] “Substantial” Utility ........................................ 7-190
[B][4][c] “Credible” Utility .......................................... 7-190
[B][4][d] “Well-Established” Utility ......................... 7-191
[B][5] The Nucleic Acid Examples of the Training Materials ........................................... 7-191
[B][5][a] “DNA Fragments” ........................................ 7-191
[B][5][b] “DNA Fragment Encoding a Full Open 
Reading Frame (ORF)” ........................................ 7-192
[C] Expressed Sequence Tags and Single Nucleotide 
Polymorphs ............................................................... 7-193
§ 7:6.4 Written Description of Nucleic Acids

[A] Satisfying the Written Description Requirement


[A][2] Fiers v. Revel .................................................. 7-197

[B] Heightened Written Description Requirement for Biotechnology and DNA Sequence Patents? .......... 7-197

[B][1] Regents of University of California v. Eli Lilly & Co. .................................................. 7-197

[B][2] Enzo Biochem, Inc. v. Gen-Probe, Inc. (Enzo I)...................................................... 7-199

[B][3] Enzo Biochem, Inc. v. Gen-Probe, Inc. (Enzo II) .......................................................... 7-200

[B][4] Amgen, Inc. v. Hoechst Marion Roussel, Inc. .... 7-202

[B][5] University of Rochester v. G.D. Searle & Co. .... 7-203

[C] Practical Implications of the Federal Circuit’s Written Description Jurisprudence ......................... 7-206

§ 7:6.5 Other Grounds for Invalidity of Nucleic Acid Inventions

[A] Anticipation ............................................................ 7-208

[B] Obviousness ........................................................... 7-209

[B][1] Amino Acid Sequences ........................................ 7-209

[B][2] Nucleic Acid Sequences ....................................... 7-209

[B][2][a] Post-KSR ..................................................... 7-209

[B][2][b] Pre-KSR ........................................................ 7-210

[C] Indefiniteness ......................................................... 7-211

[D] Enablement .......................................................... 7-211

[E] Best Mode ............................................................... 7-212

[F] Inventorship and Conception .................................. 7-212

§ 7:6.6 Claim Construction of Nucleic Acid Claims

§ 7:7 Antibodies

§ 7:7.1 What Is an Antibody?

[A] Introduction .......................................................... 7-216

[B] Monoclonal Antibodies ........................................... 7-217

[C] Commercial Applications for Antibodies .................. 7-219

§ 7:7.2 Obviousness ........................................................ 7-220

[A] Monoclonal Antibodies ........................................... 7-220

[B] Sandwich Assay ..................................................... 7-221


§ 7:7.3 Written Description .............................................. 7-222

[A] Describing Antibodies by Describing Their Target .... 7-222

[A][1] Overview of Written Description Requirement ........ 7-222

[A][2] Antibodies and DNA ........................................... 7-223

[A][3] Requirement for Describing the Antigen ............... 7-224

[A][4] Antibodies That Bind to Particular Epitopes .......... 7-224
§ 7:7.4 Enablement
[A] Enablement Supported by the Prior Art ........... 7-226
[A][1] Evidence of Enablement from the Prior Art ...... 7-226
[A][2] Enablement Based on Level of Skill in
the Art: No Undue Experimentation .................... 7-227
[B] Failed Attempts Do Not Necessarily Show
Lack of Enablement ........................................... 7-228
[C] Nascent Technology ....................................... 7-228

Chapter 8  The Hatch-Waxman Act

David O. Bickart

§ 8:1 Patent Protection and Litigation................................. 8-6
§ 8:1.1 Introduction ......................................................... 8-6
[A] Background of the Hatch-Waxman Act .................. 8-6
[B] Hatch-Waxman Act Overview ................................. 8-7
[C] Requirements for Filing an ANDA ....................... 8-8
[C][1] Labeling ................................................................. 8-10
[C][2] Active Ingredient .................................................... 8-11
[C][3] Route of Administration, Dosage Form, and
Strength .................................................................... 8-11
[C][4] Bioequivalence ......................................................... 8-12
[C][5] Drug Master File References ............................... 8-13
[D] “Suitability Petitions” for Variant Dosage Forms
and Strengths ............................................................ 8-13
[E] Paper NDAs: Section 505(b)(2) Applications ........... 8-14
§ 8:1.2 Orange Book Listing .............................................. 8-16
[A][1] What Patent Information Must Be Submitted ....... 8-16
[A][2] “Drug Product” (Formulation or Composition)
Patents ..................................................................... 8-17
[A][3] “Drug Substance” (Active Ingredient) Patents ...... 8-18
[A][4] Patents Claiming “Polymorphs” ............................. 8-19
[A][4] Method of Use Patents ............................................. 8-20
[A][5] Method of Manufacture Patents .............................. 8-20
[C] Patent Certification and Duty of Care ..................... 8-21
[D] Consequences of False Certification ....................... 8-21
[F] Orange Book Delisting Limitations ......................... 8-22
[G] Reissue Patents ......................................................... 8-23
§ 8:1.3 Patent Certifications by ANDA Applicant:
Paragraphs I, II, III, and IV ......................................... 8-23
§ 8:1.4 ANDA Filing As “Artificial Act of Infringement”
Under 35 U.S.C. § 271(e)(2) .................................... 8-26
[A] Statutory Provisions ................................................. 8-26
[B] Elements of Section 271(e)(2) Infringement Claim ....8-26
[B][1] “submit an application”....................................... 8-26
[B][2] “under Section 505(j) . . . or described in
Section 505(b)(2)”......................................................... 8-28
[B][3] “for a drug claimed in a patent or the use of
which is claimed in a patent”........................................ 8-28
[B][3][a] “drug claimed in a patent” ................................. 8-28
[B][3][a][i] Patents on Different Formulations .................. 8-29
[B][3][a][ii] Patents on Methods of Manufacture ............... 8-29
[B][3][a][iii] Product-by-Process Patents.......................... 8-29
[B][3][a][iv] Patents on Different Polymorphs................. 8-29
[B][3][a][v] Patents on Metabolites................................. 8-30
[B][3][a][vi] Patents on Intermediates............................... 8-30
[B][3][b] “or the use of which is claimed in a patent” .... 8-31
[B][4] Enforcement of Non-Orange Book Patents .......... 8-33
[C] The Section 271(e)(2) Infringement Analysis........... 8-35
[C][1] Similarities to Standard Infringement Actions..... 8-35
[C][2] Differences from Standard Infringement
Actions ....................................................................... 8-35
[C][2][a] Overview........................................................... 8-35
[C][2][b] Pre-Suit Investigation ....................................... 8-36
[C][2][c] Determining Infringement Based on ANDA.... 8-37
[C][2][d] Determining Infringement Based on
Evidence Beyond the ANDA......................................... 8-38
[C][2][e] Determining Infringement for Method
Claims ....................................................................... 8-39

§ 8:1.5 Procedural Considerations in ANDA Litigation...... 8-39
[A] Parties, Jurisdiction, and Venue.............................. 8-39
[A][1] Proper Plaintiff ..................................................... 8-39
[A][2] Proper Defendants............................................... 8-39
[A][3] Jurisdiction and Venue ......................................... 8-40
[B] Pretrial Proceedings .................................................. 8-41
[C] No Jury Trial ............................................................ 8-41

§ 8:1.6 Thirty-Month Litigation Stay Preventing
Launch of Generic....................................................... 8-42
[A] Orange Book Listing Is Prerequisite to
Thirty-Month Stay ..................................................... 8-43
[B] Beginning of the Thirty-Month Stay ....................... 8-44
[B][1] Calculated from Receipt of Notice ....................... 8-44
[B][2] The Forty-Five-Day Window ............................... 8-44
[C] Adjustment of Thirty-Month Stay ............................. 8-44
[D] Termination of Thirty-Month Stay ............................ 8-45
[D][1] Judgment of Non-Infringement, Invalidity or Unenforceability ................................................... 8-45
[D][2] Effect of Settlement ............................................ 8-46
§ 8:1.7 Remedies .................................................................. 8-46
[A] Order Precluding FDA Approval of ANDA Until Patent Expiration ............................................ 8-46
[B] Injunctive Relief ....................................................... 8-47
[C] Damages Only upon Commercial Sales of Infringing Product .................................................... 8-47
[D] Attorney Fees............................................................ 8-48
[D][1] Statutory Provisions: Sections 271(e)(4) and 285 ................................................................. 8-48
[D][2] Factors for Determining Exceptional Case ...... 8-48
[D][3] Hatch-Waxman Act Exceptional Case Litigation 8-49
[D][3][a] Baseless Certification ........................................ 8-49
[D][3][b] Willfulness ....................................................... 8-51
[D][3][c] Opinions by Patent Counsel ......................... 8-52
[D][3][d] Attorney Fees Sought by ANDA Filer Based on Allegation of Baseless Suit by Patentee 8-53
§ 8:1.8 Exemption from Infringement for Activities Related to FDA Submission .......................... 8-54
[C] Policy Behind Enactment of the Exemption .......... 8-55
[D] Situations in Which the Exemption Is Adjudicated ................................................................. 8-58
[E] Statutory Ambiguities............................................... 8-58
[F][1] Exemption Covers Class III Medical Devices .... 8-59
[F][2] Exemption Covers Class II Medical Devices ..... 8-60
[G] The “Solely for Uses Reasonably Related to” Requirement ........................................................... 8-60
[G][1] “reasonably related” ................................................ 8-60
[G][1][a] Supreme Court Weighs In: Merck v. Integra 8-60
[G][1][b] Post-Merck v. Integra ........................................ 8-62
[G][1][c] Pre-Merck v. Integra ......................................... 8-63
[G][2] “solely” ................................................................... 8-64
[G][3] Post-Product-Approval Activity ........................ 8-66
[G][4] Examples .............................................................. 8-66
[G][4][a] Exempt Activities ................................................ 8-66
[G][4][b] Non-Exempt Activities ........................................ 8-68
§ 8:2 The First Paragraph IV Applicant’s 180-Day Exclusivity

§ 8:2.1 Introduction ............................................................. 8-71

§ 8:2.2 Basic Statutory Provision: Section 355(j)(5)(B)(iv) .... 8-72

§ 8:2.3 Only the “First Applicant” Is Entitled to Exclusivity ....................................................... 8-72

[A] First ANDA with a Paragraph IV Certification for Any Patent ........................................... 8-72

[B] “Substantially Complete” ANDA ........................................ 8-72

[C] “Contains and Lawfully Maintains” a Paragraph IV Certification ........................................ 8-73

§ 8:2.4 Exclusivity Is Against Subsequent Paragraph IV ANDAs for Same Drug ............. 8-74

[A] No Exclusivity Against Authorized Generics .......... 8-75

[B] No Exclusivity Unless Subsequent ANDA Contains Paragraph IV Certification ........ 8-75

§ 8:2.5 Exclusivity Period Begins Only upon First Applicant’s “Commercial Marketing” .......... 8-75

§ 8:2.6 “Forfeiture” of 180-Day Exclusivity .......... 8-76

[A] “Failure to Market” .................................................. 8-77

[B] First Filer’s ANDA Is Withdrawn or Rejected ........ 8-78

[C] First Filer’s ANDA Is Not “Tentatively Approved” Within Thirty Months .......... 8-78

[D] All Challenged Patents Have Expired ........ 8-79

[E] First Applicant withdraws all Paragraph IV Certifications ........................................ 8-79

[F] Collusive Agreement ........................................... 8-79

§ 8:2.7 180-Day Exclusivity Under the Pre-MMA Hatch-Waxman Act .......... 8-80

[A] Pre-MMA Statutory Text ........................................ 8-80

[B] Exclusivity for Pre-MMA ANDAs .................. 8-81

[B][1] “patent-by-patent” Exclusivity .................. 8-81

[B][2] “shared” Exclusivity .... 8-82


[C][1] “first commercial marketing” .......... 8-84

[C][2] “a decision of a court . . . holding” .......... 8-84

[C][2][a] What “Holding”? .......... 8-84


[C][2][d] What Court? .......... 8-85

[D] Loss of Exclusivity .......... 8-86

§ 8:2.8 Waiver and Transfer of Exclusivity .......... 8-86
§ 8:3 “Data” Exclusivity Under the FD&C Act....................... 8-87
§ 8:3.1 Introduction .......................................................... 8-87
§ 8:3.2 New Chemical Entity Exclusivity............................. 8-87
  [A] Statutory Basis: Section 355(c)(3)(E)(ii) and
  Section 355(j)(5)(F)(ii)............................................... 8-87
  [B] Eligibility Criteria for NCE Exclusivity ..................... 8-89
    [B][1] “Active Ingredient” Means “Active Moiety”........... 8-89
    [B][2] Novel Combinations ......................................... 8-90
    [B][3] New Forms of Previously Approved Ingredients .. 8-91
      [B][3][a] Polymorphs.............................................. 8-91
      [B][3][b] Stereoisomers.......................................... 8-91
§ 8:3.3 “Other Significant Changes” Exclusivity .................. 8-92
  [A] Statutory Basis: Section 355(j)(5)(F)(iii) and (iv)..... 8-92
  [B] Eligibility Criteria for OSC Exclusivity.................. 8-92
    [B][1] “new clinical investigations” ............................ 8-92
    [B][2] “conducted or sponsored by the applicant”........... 8-93
    [B][3] “essential to approval”.................................. 8-93
  [C] “Carve-Out” Option for ANDAs ............................... 8-93
§ 8:3.4 “Orphan Drug” Exclusivity.................................. 8-94
  [B] “Orphan Drug” Eligibility Criteria for Exclusivity.... 8-95
  [C] Scope of Orphan Drug Exclusivity .......................... 8-95
    [C][1] “same drug”............................................... 8-96
    [C][1][a] “same” Structure ...................................... 8-96
    [C][1][b] “same” Clinical Performance....................... 8-96
§ 8:3.5 Pediatric “Exclusivity”...................................... 8-97
  [B] Eligibility for Pediatric Exclusivity ...................... 8-98
  [C] Interim Extension.............................................. 8-98
  [D] Label Revision Not Required................................ 8-99
  [E] Scope of Pediatric Extension................................ 8-99
    [E][1] Extension of Data-Based Exclusivity ................. 8-99
    [E][2] Extension of Patent Protection ....................... 8-100
§ 8:4 Patent Term Restoration........................................ 8-101
§ 8:4.1 Introduction .................................................... 8-101
§ 8:4.2 Eligibility for Patent Term Restoration.................. 8-102
  [A] Threshold Requirement....................................... 8-102
  [B] Five Conditions for Extension Eligibility.............. 8-104
  [C] The “First Permitted Commercial Marketing
    or Use of the Product”....................................... 8-105
    [C][1] Need Not Be the First Product Covered by the
    Patent to Receive Regulatory Approval ................... 8-105
  [C][2] Patent Cannot Merely Claim a
    New Formulation of a Previously
    Approved Active Ingredient ................................ 8-106
Chapter 9  Claim Construction

Richard G. Greco, Betty A. Ryberg & Martina Schuster

§ 9:1  General........................................................................................................... 9-2
§ 9:1.1  The Purpose of Claims.................................................................................. 9-2
§ 9:1.2  Claim Construction Is a Matter of Law...................................................... 9-3
§ 9:1.3  Claim Construction Is a Predicate for
Infringement and Invalidity.................................................................................... 9-3
§ 9:1.4  Procedure for Claim Construction.............................................................. 9-4
§ 9:2  Sources for Interpreting Claims ..................................................................... 9-5
§ 9:2.1  Precedent Prior to Phillips v. AWH............................................................. 9-7
[A]  Hierarchy of Evidence......................................................................................... 9-7
[A][1]  Intrinsic Evidence.......................................................................................... 9-7
[A][2]  Extrinsic Evidence.......................................................................................... 9-8
[B]  Superseded Focus on Ordinary Meaning........................................................ 9-9
§ 9:2.2  Phillips v. AWH........................................................................................... 9-9
[B]  Method for Construing Claims......................................................................... 9-10
§ 9:2.3  Post-Phillips Rules of Claim Construction................................................. 9-12
[A]  Patentee Acting As a Lexicographer................................................................. 9-12
[B]  Extrinsic Evidence............................................................................................. 9-13
[C]  Disclosed Embodiments.................................................................................... 9-13
[D]  Construction Preferably Does Not Render
Terms Superfluous or Differences in Terminology Meaningless........................ 9-14
[E]  Order of Method Steps...................................................................................... 9-14
[F]  Range Claims.................................................................................................... 9-15
§ 9:3  Interpretation of Common Claim Terms......................................................... 9-15
§ 9:3.1 Preambles ................................................................. 9-15
  [A] Preamble Recites Essential Structure......................... 9-15
  [B] Preamble Recites Important Steps ......................... 9-16
  [C] Preamble Provides Antecedent Basis ...................... 9-16
  [D] Reliance on Preamble During Prosecution ............... 9-17
§ 9:3.2 Transition Phrases .................................................... 9-17
  [A] “Comprising”............................................................ 9-17
  [B] “Consisting of” .......................................................... 9-18
  [C] “Consisting essentially of” ...................................... 9-18
  [D] “Group of,” “Group consisting of,” Markush Group ....................................................................... 9-19
  [E] “Whereby” .................................................................... 9-19
§ 9:3.3 Articles ..................................................................... 9-20
  [A] “a” or “an” .................................................................. 9-20
  [B] “the” ............................................................................ 9-21
§ 9:4 Construction of Means-Plus-Function Claims............... 9-21
§ 9:5 Disclaimer of Subject Matter That Literally Falls
Within Claim Language .................................................. 9-21
§ 9:6 Pharmaceutical Patents .................................................. 9-22
  § 9:6.1 Planning for Claim Construction During
Prosecution........................................................................... 9-22
  § 9:6.2 Common Construction Issues in Pharmaceutical
Patents.................................................................................. 9-23

Chapter 10 Patent Infringement

David K. Barr

§ 10:1 Introduction ................................................................. 10-2
§ 10:2 Acts Constituting Infringement ..................................... 10-3
  § 10:2.1 Direct Infringement............................................... 10-3
  § 10:2.2 Inducing Infringement......................................... 10-4
  § 10:2.3 Contributory Infringement .................................. 10-5
  § 10:2.4 Section 271(f): Infringement by Shipment from
the United States of Component of a Patented
Invention to Be Assembled Abroad ................................. 10-6
  § 10:2.5 Section 271(g): Infringement of a U.S. Process
Patent by Importing into the United States or
Offering to Sell, Selling, or Using a Product
Made by the Patented Process ........................................ 10-7
  § 10:2.6 “Divided” Infringement of Method Claim ............ 10-8
§ 10:3 Infringement Under the Doctrine of Equivalents...... 10-10
  § 10:3.1 The “All Elements” Rule..................................... 10-11
  § 10:3.2 Tests for Equivalence ........................................ 10-12
  § 10:3.3 Limitations on the Doctrine of Equivalents ........ 10-12
Chapter 11    Experimental Use Defense to Patent Infringement

Leora Ben-Ami, Christopher T. Jagoe & Peter Fratangelo

§ 11:1    Introduction .......................................................... 11-1
§ 11:2    Historical Development ............................................. 11-2
§ 11:3    Cases .................................................................. 11-3
  § 11:3.1  Roche Products, Inc. v. Bolar Pharmaceutical Co. .... 11-3
  § 11:3.2  Deuterium Corp. v. United States ......................... 11-4
Chapter 12  Government Funded Research: Bayh-Dole and Other Acts

Richard G. Greco

§ 12:1  Policy Behind Enactment of Bayh-Dole .................. 12-2
§ 12:1.1 Ownership of Government Funded Inventions
Prior to Bayh-Dole ............................................. 12-3
§ 12:1.2 The Motive for Change .................................. 12-3
§ 12:1.3 Reagan Policy Extension of Bayh-Dole to All
Contracting Parties .............................................. 12-4
§ 12:2  Overview of the Bayh-Dole Act ............................ 12-4
§ 12:2.1 “Funding Agreements” .................................... 12-4
§ 12:2.2 Potential Requirement for Written Agreement .... 12-5
§ 12:2.3 Private Party Right to Acquire Inventions
Made Under Funding Agreement ........................... 12-6
§ 12:2.4 Requirements for Acquiring Private Ownership
of an Invention Pursuant to Funding Agreement .... 12-7
[A] Notice of the Invention ........................................ 12-7
[A][1] Timing ............................................................ 12-7
[A][2] Scope of Disclosure ......................................... 12-8
[B] Election to Retain Rights to the Invention ............ 12-9
[C] Consequences of Failure to Provide Timely or
Sufficient Notice or Election .................................. 12-10
[C][1] Insufficient Disclosure: Campbell Plastics ........ 12-10
[C][2] Failure to Comply with Bayh-Dole Act As a
Defense: T.M. Patents ............................................ 12-11
[C][3] Good Practices ............................................... 12-12
[D] Filing Patent Applications .................................... 12-12
§ 12:2.5 Special Funding Agreement Requirements for
Non-Profit Corporations ........................................ 12-13
§ 12:3  Retained Government Rights in Inventions Funded
Under a Bayh-Dole Agreement ............................... 12-13
§ 12:3.1 Non-Exclusive Government License .................. 12-14
[A] Statutory Provision ............................................. 12-14
[B] Potential Impact on Patented Drugs ....................... 12-14
§ 12:3.2 March-In Rights: Federal Power to Use Privately
Owned Bayh-Dole Act Patents to Make
Inventions Publicly Available ............................... 12-15
Chapter 13  Antitrust, FTC, and State Competition Law

Stephen J. Elliott

§ 13:1  Introduction ................................................................. 13-3
§ 13:2  Sherman Act Claims .................................................. 13-4
  § 13:2.1  Elements of a Section 1 Claim .................................. 13-4
  [A]  Concerted Conduct ..................................................... 13-4
  [B]  Unreasonable Restraint of Trade .................................. 13-5
  [C]  Patent License Agreements .......................................... 13-7
  [C][1]  Analysis of Specific Agreement Terms ....................... 13-9
  [C][1][a]  Royalty Rates .................................................... 13-9
  [C][1][b]  Extending License Beyond Patent Term .................. 13-10
  [C][1][c]  Resale Price Maintenance ................................... 13-10
  [C][1][d]  Extending License Beyond Patent Subject Matter .......... 13-10
  [C][1][e]  Field of Use and Territory Restrictions ................. 13-11
  [C][1][f]  No-Challenge Provisions .................................... 13-11
  [D]  Patent Litigation Settlement Agreements ....................... 13-12
  [D][1]  Importance of Settlement Agreements ....................... 13-12
  [D][2]  Importance of Patent Monopoly ................................ 13-13
  [D][3]  FTC/DOJ Reporting Requirement ................................ 13-13
Analysis of Pharmaceutical Patent
Litigation Settlements ........................................ 13-14

Two Ends of the Spectrum:
Cardizem and Tamoxifen ........................................ 13-14

In re Cardizem CD Antitrust Litigation ...... 13-15
In re Tamoxifen Citrate Antitrust Litigation ..................................................... 13-16

Agreement by Generic Not to Market
Its ANDA Product .................................................. 13-17

Agreement Covers Unpatented Products ......13-18
Agreement Does Not End Litigation........... 13-18
Agreement Blocks Other Generics .......... 13-19

Reverse Payments .................................................. 13-20
Reverse Payments Supporting Finding
of Illegality .................................................. 13-20
Reverse Payments Not Resulting
in Finding of Illegality .................................................. 13-21

The Merits of the Underlying Patent
Litigation .................................................. 13-22

§ 13:2.2 Elements of a Section 2 Claim......................... 13-24

Relevant Market Definition........................................ 13-25
Predatory Conduct Involving Patents ..................... 13-27
Walker Process .................................................. 13-28
More Is Required to Prove a Walker-Process
Claim Than to Prove Inequitable Conduct .... 13-28
Case Upholding Finding of Walker-Process
Violation .................................................. 13-29
Case Reversing Finding of Walker-Process
Violation .................................................. 13-30
Sham Patent Litigation ........................................ 13-30
The Noerr-Pennington Doctrine ........................................ 13-30
The Professional Real Estate Exception
for Sham Litigation........................................ 13-31
Grounds for Rejecting Sham Litigation
Claims.................................................. 13-32
Cases Addressing Sham Litigation
Claims Based on Pharmaceutical Patent
Litigation.................................................. 13-33
Application of Professional Real Estate
to a Series of Related Cases ........................................ 13-35
Orange Book Listings ........................................ 13-36
Application of Noerr-Pennington ........................................ 13-36
Standard for Listing ........................................ 13-38

§ 13:2.3 Antitrust Injury Requirement................................. 13-39
Elements of Antitrust Injury ........................................ 13-40
Orange Book Listings ........................................ 13-41
Table of Contents

§ 13:2.4 Antitrust Standing Requirement .............................................. 13-41
 [A] Factors Relevant to Standing ........................................ 13-42
 [B] Overcharges ................................................................. 13-43
 [C] Suppliers ...................................................................... 13-43
 [D] Associations and Advocacy Organizations .................. 13-44
 [E] Standing in *Walker Process* Cases............................. 13-44

§ 13:3 Related State-Law Causes of Action .................................. 13-45
 § 13:3.1 State-Law Antitrust and Unfair Competition
 Claims ........................................................................... 13-45
 [A] Indirect Purchaser Claims ........................................ 13-45
 [B] Removal of Actions Asserting Claims
 Under State Law ............................................................. 13-46
 [B][2] Agreement to Drop Invalidity Challenge ............... 13-48
 [B][3] Claims Based on Settlement Agreements .............. 13-48
 [C] Statutory Requirements .............................................. 13-49
 [C][1] Choice of Law .......................................................... 13-49
 [C][2] *Noerr-Pennington* Applies to State Law
 Claims ............................................................................. 13-50
 [C][3] Application of Federal Precedents
 to Construe State Antitrust Laws ................................ 13-50

§ 13:3.2 Unjust Enrichment ......................................................... 13-51
 [A] Elements of State Law Unjust Enrichment
 Claim .............................................................................. 13-51

§ 13:4 Damages ........................................................................... 13-54
 § 13:4.1 Antitrust Damages ............................................... 13-54
 [A] Overcharges to Purchasers ....................................... 13-54
 [B] Indirect Purchasers ..................................................... 13-55
 [C] Claims by Competitors .............................................. 13-55
 [D] Period for Calculating Damages ............................... 13-56

§ 13:4.2 Disgorgement Remedy for Unjust Enrichment ........ 13-56

§ 13:5 Class Actions.................................................................. 13-56
 § 13:5.1 Rule 23(a) ............................................................... 13-57
 [A] Numerosity .................................................................. 13-57
 [B] Commonality ............................................................... 13-57
 [C] Typicality .................................................................. 13-57
 [D] Adequacy .................................................................. 13-58
 [D][1] Conflict of Interest ................................................ 13-58
 [D][2] Vigor ................................................................. 13-60

§ 13:5.2 Rule 23(b) ............................................................... 13-60
 [A] Inconsistency ............................................................. 13-60
 [B] Type of Relief ............................................................. 13-60
 [C] Predominance and Superiority .................................. 13-61
 [C][1] Predominance ....................................................... 13-61
 [C][2] Superiority ........................................................... 13-62

§ 13:5.3 The Class Action Fairness Act of 2005 ..................... 13-63
Chapter 14  Biologic and Biosimilar Drug Products

David K. Barr

§ 14:1 Introduction ................................................................. 14-2

§ 14:2 Biological Drug Product Defined ............................ 14-3

§ 14:3 FDA Approval of “Follow-On Biologics” Before the BPCIA ................................................................. 14-4

§ 14:4 The BPCIA ................................................................. 14-4

§ 14:4.1 “Biosimilar” Drug Products ..................................... 14-5

§ 14:4.2 “Interchangeable” Biosimilar Drug Products ........... 14-6

§ 14:4.3 FDA Guidelines on Biosimilar Drugs ..................... 14-7

§ 14:4.4 BPCIA Exclusivity Provisions .................................. 14-7

[A] Reference Product Exclusivity ..................................... 14-7

[A][1] Pediatric Exclusivity .............................................. 14-8

[A][2] Orphan Drug Exclusivity .......................................... 14-9

[B] Exclusivity for the First Interchangeable Biological Product .................................................. 14-9

§ 14:4.5 BPCIA’s Patent Dispute Resolution Provisions ...... 14-10

[A] Confidential Access to the Biosimilar Application and Manufacturing Information ........ 14-10


[C] Patent Resolution Negotiations ................................... 14-13

[D] Patent Infringement Actions Based on Filing of a Biosimilar Application......................... 14-13

[E] Remedies for Infringement .......................................... 14-15

[F] Later Issued or Exclusively Licensed Patents ............... 14-17

[G] Notice of Commercial Marketing and Preliminary Injunction Motions .......................... 14-17

[H] Limitation on Declaratory Judgment Actions ............ 14-18

§ 14:5 Conclusion ............................................................... 14-19

Appendix A  Glossary of Biotechnology Terminology from Case Law ....................................................... App. A-1

Appendix B  Primer on Basic Biotechnology Concepts .................................................................................. App. B-1

Appendix C  The Science of Biosimilars ................................ App. C-1

Table of Authorities ............................................................. T-1

Index .................................................................................. I-1

xlviii